Zebrafish Drug-Induced Liver Injury (DILI) Models

Introduction Model Details Phenotypic Evaluation Applications Study Examples

Introduction

Drug-induced liver injury (DILI) refers to liver damage caused by prescription drugs, over-the-counter medications, herbal products, dietary supplements, or drug metabolites. It can present as hepatocellular injury, cholestatic injury, mixed injury, steatosis, mitochondrial toxicity, immune-mediated hepatitis, or acute liver failure. Pathological features may include hepatocyte degeneration, necrosis, apoptosis, oxidative stress, bile transport disruption, inflammatory cell recruitment, and impaired liver regeneration. Clinically, DILI ranges from asymptomatic elevation of liver enzymes to jaundice, coagulopathy, encephalopathy, and liver transplantation. Acetaminophen overdose is a major cause of acute liver failure, while idiosyncratic DILI remains difficult to predict during drug development.

Current management mainly involves drug withdrawal, supportive care, N-acetylcysteine for acetaminophen poisoning, and liver transplantation in severe cases. However, early prediction of hepatotoxicity remains challenging because DILI is influenced by drug metabolism, dose, host susceptibility, mitochondrial stress, immune activation, and transporter function. Zebrafish DILI models provide a rapid in vivo platform to evaluate liver injury, hepatotoxicity mechanisms, hepatoprotective efficacy, and early safety liabilities before advancing candidates into rodent or clinical studies.

Why Zebrafish?

Conserved Hepatic Metabolism: Conserved hepatic metabolism supports translational DILI research.
Direct Liver Imaging: Transparent larvae enable direct liver imaging.
Liver-Specific Reporters: Liver-specific reporter lines allow rapid hepatotoxicity scoring.
High-Throughput Screening: Small size supports medium- to high-throughput screening.
Combined Endpoints: Efficacy and toxicity endpoints can be assessed together.

Available Zebrafish Disease Models

Our DILI platform includes acetaminophen, reporter-based, anti-tuberculosis, and cholestatic / mitochondrial configurations:

Model Name	Induction Method	Features
Acetaminophen / Paracetamol-Induced Zebrafish DILI Model	Zebrafish larvae are exposed to acetaminophen after liver formation, commonly from 3–5 days post-fertilization onward. Exposure concentration and duration are optimized to induce measurable liver injury while maintaining sufficient survival. Candidate hepatoprotective compounds can be added before, during, or after APAP exposure.	One of the most commonly used zebrafish DILI models. It reproduces key features of acute hepatotoxicity, including reduced liver size, liver fluorescence loss in reporter lines, hepatocyte injury, oxidative stress, glutathione-related metabolic stress, and treatment response to N-acetylcysteine.
Liver-Specific Fluorescent Reporter Hepatotoxicity Model	Transgenic zebrafish larvae expressing liver-specific fluorescent proteins, such as lfabp10a / fabp10a reporter lines, are exposed to test compounds or reference hepatotoxins in multi-well plates. Liver area, fluorescence intensity, and morphology are quantified by imaging.	Highly suitable for CRO hepatotoxicity screening. Enables rapid visual assessment of liver damage, liver degeneration, delayed liver development, and dose-response toxicity. Often used for compound ranking and early safety liability detection.
Anti-Tuberculosis Drug-Induced Liver Injury Model	Zebrafish larvae are treated with anti-tuberculosis drugs such as isoniazid, rifampicin, pyrazinamide, or defined combinations. Exposure may be combined with genetic or metabolic susceptibility settings depending on study goals.	Relevant for clinically important DILI caused by anti-infective drugs. Useful for evaluating oxidative stress, inflammatory activation, hepatocyte apoptosis, liver morphology changes, and hepatoprotective interventions.
Cholestatic / Mitochondrial DILI Model	Larvae are exposed to compounds associated with bile transport disruption, mitochondrial dysfunction, or mixed hepatotoxicity, such as cyclosporine A, amiodarone, bosentan-like agents, or customized test articles. Treatment windows are selected based on liver maturity and compound solubility.	Supports mechanistic studies of cholestatic injury, mitochondrial stress, lipid dysregulation, bile-related toxicity, and transporter-associated liver injury. Useful for distinguishing general toxicity from liver-focused injury patterns.

Phenotypic Evaluation

Oxidative Stress, Metabolism & Mitochondrial Dysfunction

ROS levels
Glutathione depletion or redox imbalance
Lipid peroxidation markers
Mitochondrial membrane potential
Expression of cyp, gsta, nrf2, hmox1, and related detoxification genes

Inflammation, Cholestasis & General Safety

Inflammatory markers such as tnfa, il1b, il6
Neutrophil / macrophage recruitment
Bile transport or cholestasis-related signals
Survival, body morphology, cardiac circulation, and developmental toxicity

Hepatocellular Injury & Cell Death

Hepatocyte degeneration
Apoptosis or necrosis markers
TUNEL or caspase-related readouts
Histological liver damage score
ALT / AST-related biochemical indicators when applicable

Liver Morphology & Functional Phenotype

Liver size / liver area
Liver fluorescence intensity in reporter lines
Liver opacity or degeneration
Delayed liver development
Hepatomegaly or liver shrinkage

Key Applications

Early Hepatotoxicity Screening: In vivo ranking of drug candidates, metabolites, natural products, or formulation components for liver toxicity risk.
Acetaminophen-Induced Liver Injury Studies: Evaluation of APAP hepatotoxicity, oxidative stress, metabolic activation, and hepatoprotective response.
Hepatoprotective Compound Evaluation: Testing of small molecules, biologics, antioxidants, natural products, and dietary supplement ingredients for liver protection.
Mechanism-of-Action Studies: Investigation of oxidative stress, mitochondrial dysfunction, bile transport disruption, inflammation, apoptosis, and detoxification pathways.
Translational Safety Assessment: Bridging cell-based hepatotoxicity assays and mammalian studies using a rapid whole-organism toxicology platform.

Study Examples

Acetaminophen-induced liver injury model for hepatoprotection testing. The authors used zebrafish larvae to establish an acetaminophen-induced liver injury model and evaluate hepatoprotective interventions. APAP exposure produced measurable liver injury, and the study tested the effects of prostaglandin E2-related signaling and N-acetylcysteine. The results showed that PGE2-regulated Wnt signaling and NAC acted synergistically to protect the liver from acetaminophen toxicity.

Fig. 1. Acetaminophen exposure induces liver injury in zebrafish larvae, which can be reduced by hepatoprotective treatment (North TE, Babu IR, et al., 2010).

Start Your Zebrafish DILI Study

Our zebrafish drug-induced liver injury models support early hepatotoxicity screening, APAP-induced liver injury studies, anti-tuberculosis drug hepatotoxicity evaluation, cholestatic injury assessment, and hepatoprotective compound testing.

Contact Our Scientists

Reference

North TE, Babu IR, et al. PGE2-regulated Wnt signaling and N-acetylcysteine are synergistically hepatoprotective in zebrafish acetaminophen injury. Proceedings of the National Academy of Sciences of the United States of America 107(40), 17315–17320 (2010). doi:10.1073/pnas.1008209107.

For research use only. Not intended for any clinical use.